[1] Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders[J]. Mayo Clin Pro, 2017, 92:663-679.
[2] Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica[J]. Lancet Neurol, 2007, 6:805-815.
[3] Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85:177-189.
[4] Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians[J]. Neurology, 2011, 76:1589-1595.
[5] Matsuoka T, Matsushita T, Kawano Y, Osoegawa M, Ochi H, Ishizu T, Minohara M, Kikuchi H, Mihara F, Ohyagi Y, Kira J. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese[J]. Brain, 2007, 130(Pt 5):1206-1223.
[6] Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain[J]. Ann Neurol, 2012, 71:323-333.
[7] Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms[J]. Ann Neurol, 2011, 70:943-954.
[8] Reeves HM, Winters JL. The mechanisms of action of plasma exchange[J]. Br J Haematol, 2014, 164:342-351.
[9] National Health Commission Expert Committee Office of Diagnosis. Guidelines for the diagnosis and treatment of rare diseases (2019 edition)[S/OL]. 2019[2020-09-20]. http://www.gov.cn/fumu/2019-02/28/content_5369203. Beijing:NHC, 2019.[国家卫生健康委罕见病诊疗与保障专家委员会办公室. 罕见病诊疗指南(2019年版)[S/OL]. 2019[2020-09-20]. http://www.gov.cn/fumu/2019-02/28/content_5369203.
[10] Kitley J, Palace J. Therapeutic options in neuromyelitis optica spectrum disorders[J]. Expert Rev Neurother, 2016, 16:319-329.
[11] Kosiyakul P, Songwisit S, Ungprasert P, Siritho S, Prayoonwiwat N, Jitprapaikulsan J. Effect of plasma exchange in neuromyelitis optica spectrum disorder:a systematic review and Meta-analysis[J]. Ann Clin Transl Neurol, 2020. [Epub ahead of print]
[12] Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A. Azathioprine:tolerability, efficacy, and predictors of benefit in neuromyelitis optica[J]. Neurology, 2011, 77:659-666.
[13] Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of neuromyelitis optica with mycophenolate mofetil:retrospective analysis of 24 patients[J]. Arch Neurol, 2009, 66:1128-1133.
[14] Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica[J]. Arch Neurol, 2011, 68:473-479.
[15] Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder[J]. JAMA Neurol, 2013, 70:1110-1117.
[16] Neuroimmunology Branch, Neuroimmunology Society of China; Neuroimmunology Group, Neurology Branch, Chinese Medical Association; Neuroimmunology Professional Committee, Neurology Branch, Chinese Medical Doctor Association. Chinese guideline for diagnosis and treatment of neuromyelitis optic spectrum diseases[J]. Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2016, 23:155-166. [中国免疫学会神经免疫学分会, 中华医学会神经病学分会神经免疫学组, 中国医师协会神经内科分会神经免疫专业委员会. 中国视神经脊髓炎谱系疾病诊断与治疗指南[J]. 中国神经免疫学和神经病学杂志, 2016, 23:155-166.]
[17] Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum):a double-blind, randomised placebo-controlled phase 2/3 trial[J]. Lancet, 2019, 394:1352-1363.
[18] Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice[J]. Brain, 2010, 133(Pt 2):349-361.
[19] Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders:an open-label pilot study[J]. Lancet Neurol, 2013, 12:554-562.
[20] Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, Ogawa M, Toda T, Yamamura T. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica[J]. Proc Natl Acad Sci USA, 2011, 108:3701-3706.
[21] Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J. Trial of satralizumab in neuromyelitis optica spectrum disorder[J]. N Engl J Med, 2019, 381:2114-2124.
[22] Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder:a randomised, double-blind, multicentre, placebo-controlled phase 3 trial[J]. Lancet Neurol, 2020, 19:402-412.
[23] Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmström P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis[J]. J Neuroimmunol, 2004, 152(1/2):183-190.
[24] Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth[J]. J Exp Med, 1999, 189:1747-1756.
[25] Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember:novel TNF ligands as therapeutic targets[J]. Nat Revi Drug Discov, 2006, 5:235-246.
[26] Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI[J]. Curr Biol, 2000, 10:785-788.
[27] Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases[J]. J Immunology, 2002, 169:4314-4321.
[28] Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease[J]. Nature, 2000, 404:995-999.
[29] Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE):52-week data (APRIL-SLE randomised trial)[J]. Ann Rheum Dis, 2015, 74:2006-2015.
[30] Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG. Atacicept in combination with MMF and corticosteroids in lupus nephritis:results of a prematurely terminated trial[J]. Arthritis Res Ther, 2012, 14:R33.
[31] Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, Nestorov I. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus[J]. Lupus, 2009, 18:547-555.
[32] Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, Isenberg D. Efficacy and safety of atacicept in patients with systemic lupus erythematosus:results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase Ⅱ b study[J]. Arthritis Rheumatol, 2018, 70:266-276.
[33] Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy:results of a phase Ⅱ, randomized, placebo-controlled, dose-finding trial[J]. Arthritis Rheum, 2011, 63:1793-1803.
[34] van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate:results of a phase Ⅱ, randomized, placebo-controlled trial[J]. Arthritis Rheum, 2011, 63:1782-1792.
[35] Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J. Atacicept in multiple sclerosis (ATAMS):a randomised, placebo-controlled, double-blind, phase 2 trial[J]. Lancet Neurol, 2014, 13:353-363.
[36] Sergott RC, Bennett JL, Rieckmann P, Montalban X, Mikol D, Freudensprung U, Plitz T, van Beek J. ATON:results from a phase Ⅱ randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis[J]. J Neurol Sci, 2015, 351(1/2):174-178.
[37] Gordon C, Bassi R, Chang P, Kao A, Jayne D, Wofsy D, Fleuranceau-Morel P. Integrated safety profile of atacicept:an analysis of pooled data from the atacicept clinical trial programme[J]. Rheumatol Adv Pract, 2019, 3:rkz021.
[38] Kaegi C, Steiner UC, Wuest B, Crowley C, Boyman O. Systematic review of safety and efficacy of atacicept in treating immune-mediated disorders[J]. Front Immunol, 2020, 11:433.
[39] Willen D, Uhl W, Wolna P, Papasouliotis O, Yalkinoglu Ö. Safety, tolerability, pharmacokinetics, and pharmacodynamics of atacicept in a randomized trial in healthy caucasian and Japanese subjects[J]. Eur J Drug Metab Pharmacokinet, 2020, 45:27-40.